Introduction
First reported in 1968, acquired von Willebrand syndrome (AVWS) is a rare disorder of haemostasis that mimics congenital von Willebrand disease (VWD) and can result in life-threatening bleeding complications [1] . VWD results from a hereditary defect and is often accompanied by a family history of bleeding problems. AVWS, in contrast, is an acquired condition that is more commonly seen in elderly patients without a prior history of bleeding and frequently occurs as a result of an underlying medical condition, such as monoclonal hematoproliferative disorders (most commonly an IgG monoclonal gammopathy), malignancy, autoimmune disorders or cardiac disorders [2] .
Bleeding in both VWD and AVWS is a result of abnormalities of the von Willebrand factor (VWF), a large multimeric glycoprotein that is essential to primary haemostasis through the regulation of platelet adhesion and aggregation at the site of vascular injury. VWF also increases the half-life of factor VIII in circulation through stabilization as a carrier protein [3] . Hereditary VWD is separated into three main types of disease. Type 1 disease is the most common type of VWD and is inherited via an autosomal dominant pattern that leads to mild to moderate bleeding from a decreased quantity of structurally normal VWF [4] [5] [6] . Type 2 disease consists of four subtypes of VWD (2A, 2B, 2M and 2N) that is also largely inherited as an autosomal dominant disease (2N and rare cases of 2A and 2M can be autosomal recessive) and leads to generally mild to moderate bleeding as a result of qualitative and functional defects in the VWF [4] [5] [6] . Type 3 disease is a rare autosomal recessive condition that can result in severe bleeding resembling factor VIII deficiency as a result of the complete absence of VWF [4] [5] [6] .
In contrast, AVWS is an acquired condition characterized by the increased clearance of qualitatively normal VWF. This increased clearance results in a relative deficiency of both VWF and factor VIII [2] and may occur through several potential mechanisms: autoantibodies to VWF that either inhibit functional sites or increase clearance from circulation; nonspecific antibodies that form circulating immune complexes and favour VWF clearance by Fc-bearing cells; proteolytic degradation and adsorption onto malignant clone cells; or increased shear stress as in cardiac valvular disorder [7, 8] . The diagnosis of AVWS is often difficult given the heterogeneity in presentation of the disease and laboratory results and lack of a specific diagnostic test [9] . In this report, we highlight the diagnostic challenges and importance of proper diagnosis in a patient with AVWS who was misdiagnosed with type III von Willebrand disease for 30 years.
Case report
An 82-year-old man was diagnosed with presumed type III VWD at the age of 50 after prolonged bleeding with phlebotomy, an abnormal bleeding time and prolonged activated partial thrombin time (aPTT). He had no prior personal or family history of bleeding problems. Over the next 30 years, he underwent several orthopaedic procedures including knee and hip replacements for which he was treated preoperatively with factor VIII/VWF concentrate on at least two separate occasions. Postoperatively, he was noted to have had increased bleeding and minimal correction of factor VIII levels despite the administration of factor VIII/VWF concentrate.
In 2013, he presented with a spontaneous lower extremity intramuscular haematoma and underwent haematoma evacuation and fasciotomy. He was treated at home with a 100% correction dose of factor VIII/VWF concentrate at 48 units/kg twice daily, but presented to the hospital when he continued to bleed from the surgical site requiring at least five units of blood. Initial laboratory evaluation revealed a prolonged aPTT of 146.2 s (normal 25-37 s) with normal prothrombin time and fibrinogen, low factor VIII activity (21%), low VWF antigen (vWF: Ag) (26%) and low VWF activity (vWF:RCof) (<13%). Von Willebrand multimer analysis confirmed type III VWD with barely detectable multimers ( Fig. 1 ). After attempted replacement to 100% activity with VWF containing concentrate, peak activity and factor levels remained low: factor VIII activity 22-33%, vWF:Ag 22-50% and vWF:RCof undetectable ( Table 1 ). The lack of response to infused VWF concentrates was concerning for a VWF inhibitor. A VWF propeptide antigen later returned at 151 IU/dl (normal 62-183), consistent with increased destruction of VWF as seen in AVWS.
Given the concern for an inhibitor, a serum protein electrophoresis was checked and demonstrated the presence of an IgG paraprotein of 0.29 g/dl. Evaluation with a bone marrow biopsy and skeletal survey confirmed a diagnosis of monoclonal gammopathy of undetermined significance (MGUS). Given the IgG MGUS and clinically significant VWF inhibiting autoantibodies, intravenous immunoglobulin (IVIG) was administered at a dose of 1 gm/kg i.v. daily for 2 consecutive days. Within 48 h of IVIG administration, complete correction of his coagulation profile was noted along with cessation of bleeding. Repeat multimer testing showed no evidence of VWD. A 1 : 1 mixing study of the ristocetin cofactor assay revealed no inhibitor, but the patient was felt clinically to have AVWS given the response to IVIG. The patient's AVWS recurred within 3 weeks of IVIG therapy and was again treated with IVIG with good response. His AVWS recurred 3 weeks after the second IVIG dosing and has not been retreated with IVIG as his bleeding has resolved.
Discussion
Abnormal bleeding symptoms in an elderly patient without a personal or family history of bleeding should prompt an investigation for AVWS, especially in the setting of laboratory abnormalities suggestive of VWD. Laboratory evaluation in AVWS will usually be consistent with a diagnosis of VWD and will show a prolonged activated partial thrombin time and PFA-100 (platelet function analyser) with normal prothrombin time and platelet count [8] . Specific evaluation of VWF will usually reveal a decrease in the von Willebrand antigen, von Willebrand activity and factor VIII activity, though increases can be seen. There is commonly a reduction in the antigen to activity level and the collagen binding to antigen ratio [8] . Multimer analysis usually reveals a loss of high molecular weight multimers, consistent with type I or type II VWD [2, 8] . To specifically diagnose AVWS, mixing studies can demonstrate the presence of an autoantibody in 15% of patients [8] . In IgG MGUS, an autoantibody may not be detected because the antibody is directed against nonfunctional epitopes or the inhibitor is saturated in complexes with VWF, preventing detection. Other potential inhibitor testing includes ristocetin-induced agglutination cofactor, ELISA, the demonstration of a neutralizing antivWF inhibitor with collagen-binding activity and the analysis of the VWF propeptide, but these tests are not standardized and can lead to false positive or negative results [1, 2, 9] .
As laboratory evaluation alone is often insufficient to distinguish VWD from AVWS, clinical suspicion and recognition of risk factors is critical. A careful patient history and examination should be undertaken to look for evidence of AVWS-associated conditions. A routine complete blood count and serum protein electrophoresis can help to exclude an underlying haematologic condition or monoclonal gammopathy. Ultimately, a diagnosis should be made when a patient fails to respond as expected to treatment for VWD with von Willebrand concentrate, as in the case of our patient [10] .
Treatment for patients with AVWS should be aimed at the underlying causative disease and remains difficult, as there are no specific treatment guidelines. In some circumstances, treating the underlying disease is not possible or not practical as in the case of critical bleeding. In these situations, the underlying cause of the AVWS is essential to determine the most appropriate treatment to restore haemostasis. As in our case, patients with IgG MGUS often respond to treatment with IVIG (1 g/kg daily for 2 days) with a correction of laboratory abnormalities and decreased bleeding complications [7, 11] . About 2 g/kg of IVIG should be given over 2 days instead of being divided into smaller doses over a longer period of time to achieve maximum effects, but may need to be repeated, as the average duration of effect from IVIG is 3 weeks [7] . The proposed mechanism of action of IVIG includes elimination of circulating immune complexes by monomeric Ig or the blockage of Fc-receptors on the reticulo-endothelial system [7] . Systemic steroids have shown efficacy in AVWS associated with immunologic diseases but not with IgG MGUS because the monoclonal IgG protein continues to act as an anti-VWF autoantibody [1] . For IgM monoclonal gammopathies, IVIG has not been shown effective and plasmapharesis is recommended [7] . Other treatment modalities, although with less literature support, include recombinant factor VIIa and antifibrinolytics (usually as adjuvant therapy with desmopressin or von Willebrand containing concentrates) [1] .
Conclusion
Although there is heterogeneity to the clinical presentation and laboratory evaluation between congenital VWD and AVWS, the latter should be considered when the onset of bleeding occurs later in life and without previous personal or family history of bleeding or when a patient has a known AVWS-associated disorder. Lack of standardization of laboratory methods for antibody identification and characterization makes diagnosis challenging, highlighting the need for clinical suspicion and careful history and physical examination. The goals of treatment should be aimed at resolving the underlying associated disorder, controlling acute bleeding, prevention of bleeding in high-risk situations and obtaining long-term remission. 
